



Validation of novel targets for the treatment of heart failure

Summary/overview:

The AstraZeneca [Genomics Initiative](#) that was launched in April 2016 has a bold ambition of analysing two million genomes and sequencing 500,000 genomic samples from our own clinical trials by 2026. This will be made possible through a unique network of global, pioneering genomics collaborators including partners such as Regeneron, the UK Biobank, and the FinnGen consortium. We have a shared ambition to uncover the genetic drivers of disease, identify new drug targets and match patients to the therapies most likely to benefit them.

As part of the Genomics Initiative, we have analysed genomes from patients with preserved and reduced heart failure (HFpEF and HfrEF respectively) and identified a list of novel targets. The next step is to validate the function of 30 selected targets using human iPSC-derived cardiomyocytes in 4 different assays to study calcium/contractility, hypertrophy, proliferation and mitochondrial function. The work will be performed at CVRM Bioscience, HF department at the AstraZeneca site in Gothenburg. If the results are good, we will publish in a high quality journal. Feel free to reach out to the contact person below if you want to hear more about the work!

Experience required/preferred:

Experience with cell culture and basic molecular techniques are required. Knowledge from one or several functional analysis methods (e.g. contractility or metabolism) is a plus.

If this sounds interesting to you, please send your CV and a motivation letter to:

Malin Jonsson Boezelman, PhD

AstraZeneca

CVRM IMED, Bioscience | Heart Failure and Cardiac Regeneration In Vitro Team

Pepparedsleden 1, Mölndal, Sweden, 431 83

Tel +46-(0)31-776 2756

malin.jonssonboezelman@astrazeneca.com